BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Lymphoma (DLBCL, follicular, Hodgkin, MCL) clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for lymphoma: 663 (315 sponsors; 63 newly posted in the last 180 days, 28 stopped in the last 180 days; 24 new-entrant sponsors). Momentum score 11.2, rank 61 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 11, Phase 1 189, Phase 2 258, Phase 3 115, Phase 4 8, N/A 82.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Merck Sharp & Dohme LLC MRK | 20 | P2 11, P3 9 | 3 | 2 |
| BeOne Medicines ONC | 16 | P3 7, P1 2, P2 7 | 3 | 1 |
| Hoffmann-La Roche | 18 | P3 6, P1 3, P2 7, NA 2 | 0 | 2 |
| Genmab GMAB | 14 | P3 6, P2 7, P1 1 | 0 | 1 |
| AstraZeneca AZN | 22 | P3 5, P1 2, P2 13, NA 2 | 2 | 3 |
| Beijing InnoCare Pharma Tech Co., Ltd. | 9 | P2 4, P3 5 | 2 | 1 |
| Regeneron Pharmaceuticals REGN | 9 | P2 2, P3 5, P1 1, NA 1 | 1 | 1 |
| Loxo Oncology, Inc. | 6 | P3 5, P2 1 | 0 | 0 |
| Novartis Pharmaceuticals NVS | 12 | P2 4, NA 2, P1 3, P3 3 | 0 | 3 |
| Ascentage Pharma Group Inc. AAPG | 10 | P2 3, P3 3, P1 4 | 0 | 2 |
| Incyte Corporation INCY | 8 | P1 3, P2 2, P3 3 | 1 | 2 |
| Dizal Pharmaceuticals | 7 | P3 3, P2 4 | 1 | 0 |
| Kite, A Gilead Company | 7 | P1 2, P3 3, P2 2 | 0 | 0 |
| Janssen Research & Development, LLC | 11 | P1 7, P2 2, P3 2 | 0 | 2 |
| Acerta Pharma BV | 6 | P2 3, P3 2, P1 1 | 0 | 2 |
| Celgene | 6 | P1 1, P2 3, P3 2 | 0 | 1 |
| Sinocelltech Ltd. | 4 | P2 1, P3 2, P1 1 | 1 | 0 |
| AbbVie ABBV | 11 | P1 5, NA 2, P3 1, P2 3 | 1 | 2 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | 8 | P2 4, P1 3, P3 1 | 2 | 1 |
| Nurix Therapeutics, Inc. NRIX | 6 | P1 3, P2 2, P3 1 | 0 | 1 |
| Pfizer PFE | 6 | P1 1, P4 2, NA 1, P3 1, P2 1 | 0 | 0 |
| Ono Pharmaceutical Co., Ltd. | 5 | P3 1, P1 3, P2 1 | 0 | 0 |
| Evopoint Biosciences Inc. | 4 | P2 3, P3 1 | 1 | 1 |
| Amgen AMGN | 3 | P2 2, P3 1 | 0 | 0 |
| Chengdu Zenitar Biomedical Technology Co., Ltd | 3 | P2 2, P3 1 | 0 | 1 |
Recently stopped trials
- NCT02875548 Epizyme, Inc. - terminated: Sponsor decision; no additional participant enrollment was anticipated. A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazem
- NCT05660967 Genmab - terminated: The study was terminated because sufficient data had been collected to meet the objectives of the development program. No new or unexpected Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
- NCT05879744 Cullinan Therapeutics Inc. - terminated: Strategic business decision A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
- NCT05291390 Armaceutica, Inc. - suspended: Change of protocol Pyronaridine in Acute Myeloid Leukemia (AML)
- NCT05664217 Nektar Therapeutics - terminated: Sponsor decided to end the study NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
- NCT05144334 Biotheryx, Inc. - terminated: Business decision A Study of BTX-1188 in Subjects With Advanced Malignancies
- NCT05403450 Taiho Oncology, Inc. - terminated: ASTX660-03 was closed according to protocol as no safe and tolerable dosing for the combination of tolinapant and decitabine/cedazuridine wa A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Partici
- NCT00893516 Emergent BioSolutions - terminated: Portfolio consolidation. CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma
- NCT00421213 Alaunos Therapeutics - terminated: Sponsor stopped enrollment at 50 of 70 planned patients because an activity signal had been observed in lymphoma and further enrollment woul Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
- NCT04401020 Sanofi - terminated: Sponsor decision based on limited clinical benefit observed in both Multiple Myeloma and Non-Hodgkin Lymphoma cohorts First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
- NCT07048353 Shandong Qilu Cell Therapy Engineering Technology Co., Ltd - suspended: Because of changes in domestic regulations, we need to complete the local filing process first before continuing the research. CD30 CAR-T in the Treatment of CD30 Positive Lymphoma
- NCT04601584 AO GENERIUM - terminated: The sponsor discontinued the development of the drug for reasons other than safety. GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
- NCT05279300 CStone Pharmaceuticals - suspended: The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing sch A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
- NCT06622226 Ono Pharmaceutical Co., Ltd. - terminated: Sponsor decided to discontinue development of the compound A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- NCT03598608 Merck Sharp & Dohme LLC - terminated: Business Reason Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Parti
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Karyopharm Therapeutics Inc KPTIQ | NCT02227251 Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Diffuse Large B-cell Lymphoma | active not recruiting | 244 |
| 2026-12 est. | P2/P3 | Karyopharm Therapeutics Inc KPTIQ | NCT04442022 A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma | active not recruiting | 501 |
| 2026-12 est. | P2 | Ascentage Pharma Group Inc. AAPG | NCT05147467 Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | recruiting | 75 |
| 2026-12 est. | P1/P2 | Step Pharma, SAS | NCT05463263 A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | Lymphoma, B-Cell; Lymphoma, T-Cell | recruiting | 180 |
| 2026-12 est. | P1/P2 | Dren Bio | NCT05475925 A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | LGLL - Large Granular Lymphocytic Leukemia; Primary Cutaneous Gamma-Delta T-Cell Lymphoma; Primary C | recruiting | 200 |
| 2026-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05623982 A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Non-hodgkin's Lymphoma | recruiting | 40 |
| 2026-12 est. | P1/P2 | Beam Therapeutics Inc. BEAM | NCT05885464 A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL | Lymphoblastic Lymphoma; T-Cell Lymphoblastic Leukemia/Lymphoma; Lymphoblastic Leukemia | active not recruiting | 5 |
| 2026-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06066203 A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies | Non-hodgkin's Lymphoma | recruiting | 40 |
| 2026-12 est. | P2 | Ryvu Therapeutics SA | NCT06534437 MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) | Non-Hodgkin Lymphoma, B-cell | recruiting | 178 |
| 2026-12-23 est. | P1/P2 | Cho Pharma Inc. | NCT05950165 A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | active not recruiting | 37 |
| 2026-12-28 est. | P1/P2 | Hoffmann-La Roche | NCT04077723 A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination Wit | Lymphoma, Non-Hodgkin | active not recruiting | 498 |
| 2026-12-30 est. | P2 | Chengdu Zenitar Biomedical Technology Co., Ltd | NCT05563844 Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) | Diffuse Large B Cell Lymphoma,DLBCL | active not recruiting | 74 |
| 2026-12-30 est. | P2 | Allotera Therapeutics | NCT06514794 A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) | T-cell Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma | recruiting | 125 |
| 2026-12-31 est. | P3 | Janssen Research & Development, LLC | NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; | active not recruiting | 539 |
| 2026-12-31 est. | P2 | Miltenyi Biomedicine GmbH | NCT04792489 DALY II USA/ MB-CART2019.1 for DLBCL | Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma; High Grade | recruiting | 315 |
| 2026-12-31 est. | P2 | GeoVax, Inc. GOVX | NCT04977024 SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer | COVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia; Lymphoma; Plasma Cell Myel | active not recruiting | 63 |
| 2026-12-31 est. | P1/P2 | Pell Bio-Med Technology Co., Ltd. | NCT05326243 Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Large B-cell Lymphoma; Fol | active not recruiting | 49 |
| 2026-12-31 est. | P1/P2 | Genfleet Therapeutics (Shanghai) Inc. | NCT06375733 A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL | Large B-cell Lymphoma | recruiting | 51 |
| 2026-12-31 est. | P1/P2 | Xenothera SAS | NCT06495723 Polyspecific Antibodies in Lymphoproliferative T-cell Disorders | Peripheral T Cells Lymphoma (PTCL) | recruiting | 54 |
| 2027-01 est. | P2 | Evopoint Biosciences Inc. | NCT06702605 To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma | Relapsed/Refractory Peripheral T Cell Lymphoma | not yet recruiting | 50 |
| 2027-01 est. | P2 | Zhejiang Teruisi Pharmaceutical Inc. | NCT06886139 A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL. | CD20-positive Diffuse Large B-Cell Lymphoma | not yet recruiting | 139 |
| 2027-01-31 est. | P2 | Miltenyi Biomedicine GmbH | NCT07288879 DALY II Japan/MB-CART2019.1 for DLBCL | DLBCL - Diffuse Large B Cell Lymphoma; CAR T Cell Therapy | recruiting | 31 |
| 2027-02-12 est. | P2 | Merck Sharp & Dohme LLC MRK | NCT03407144 Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | Hodgkin Lymphoma | active not recruiting | 340 |
| 2027-02-13 est. | P3 | Epizyme, Inc. | NCT04224493 A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in | Relapsed/Refractory Follicular Lymphoma; Follicular Lymphoma; Refractory Follicular Lymphoma | active not recruiting | 599 |
| 2027-02-15 est. | P3 | Acerta Pharma BV | NCT02972840 A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | Lymphoma, Mantle Cell | active not recruiting | 635 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P3 | Oncternal Therapeutics, Inc | NCT05431179 A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma | Lymphoma, Mantle-Cell; Lymphoma; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferat | withdrawn | |
| 2026-10-29 | P2 | Hoffmann-La Roche | NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusio | Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, | completed | 534 |
| 2026-10-22 | P1/P2 | Hoffmann-La Roche | NCT03533283 An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Non-Hodgkins Lymphoma | completed | 211 |
| 2026-10-13 est. | P1/P2 | GlaxoSmithKline | NCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | Melanoma; Hodgkin Lymphoma; High and Low Grade Glioma; Glioblastoma Multiforme (GBM); Diffuse Intrin | active not recruiting | 83 |
| 2026-10-01 est. | P2 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | NCT07188610 PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma | CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma | recruiting | 100 |
| 2026-10 est. | P3 | Loxo Oncology, Inc. | NCT04965493 A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/ | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | active not recruiting | 600 |
| 2026-09-30 est. | P2 | Hebei Senlang Biotechnology Inc., Ltd. | NCT07244380 Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. | T Lymphoblastic Leukemia/Lymphoma | not yet recruiting | 38 |
| 2026-09-30 est. | P1/P2 | Turning Point Therapeutics, Inc. TPB | NCT04094610 A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Locally Advanced Solid Tumors; Metastatic Solid Tumors; Lymphoma; Primary CNS Tumors | recruiting | 75 |
| 2026-09-01 est. | P1/P2 | Zhejiang Teruisi Pharmaceutical Inc. | NCT07035379 A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone(T-CHP) in Previously Untreated Patients With CD20-positive DLBCL | Diffuse Large B-Cell Lymphoma (DLBCL) | not yet recruiting | 66 |
| 2026-09-01 est. | P3 | Incyte Corporation INCY | NCT04824092 Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | Diffuse Large B-cell Lymphoma | active not recruiting | 899 |
| 2026-08-11 | P1/P2 | Bristol-Myers Squibb BMY | NCT06035497 A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas i | Relapsed or Refractory T-cell Lymphomas | active not recruiting | 83 |
| 2026-07-31 est. | P2 | Xynomic Pharmaceuticals, Inc. | NCT03936153 Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Diffuse Large B-cell Lymphoma (DLBCL) | recruiting | 170 |
| 2026-07-14 | P1/P2 | Ossium Health, Inc. | NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malign | Acute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Acute Biphenotypic Leukemia; A | active not recruiting | 12 |
| 2026-06-30 est. | P2 | NOBO Medicine | NCT06737250 NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL | Primary CNS Lymphoma (PCNSL) | recruiting | 33 |
| 2026-06-30 est. | P2 | Chengdu Zenitar Biomedical Technology Co., Ltd | NCT06485219 A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma | Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL); Cutaneous T-cell Lymphoma (CTCL) | active not recruiting | 50 |
| 2026-06-22 est. | P2 | Cellectar Biosciences, Inc. CLRB | NCT02952508 Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom | Waldenstrom Macroglobulinemia; Multiple Myeloma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lym | active not recruiting | 120 |
| 2026-06-20 est. | P1/P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05055791 A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies | Acute Myeloid Leukemia; Lymphoma; Multiple Myeloma | unknown | 312 |
| 2026-06-19 | P2 | Celgene | NCT06425302 A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma | Lymphoma, Follicular | active not recruiting | 95 |
| 2026-06-17 | P2 | Regeneron Pharmaceuticals REGN | NCT03888105 A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Ot | B-cell Non-Hodgkin Lymphoma (B-NHL) | active not recruiting | 515 |
| 2026-06-10 | P2 | Dizal Pharmaceuticals | NCT06539195 DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) | Diffuse Large B Cell Lymphoma | completed | 59 |
| 2026-06-10 | P2 | Genmab GMAB | NCT05660967 Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma | terminated | 111 |
| 2026-06-03 | P3 | Hoffmann-La Roche | NCT04712097 A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a | Relapsed or Refractory Follicular Lymphoma | active not recruiting | 478 |
| 2026-06 est. | P1/P2 | Juventas Cell Therapy Ltd. | NCT06005649 Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | Non-hodgkin Lymphoma | withdrawn | |
| 2026-06 est. | P2 | Actuate Therapeutics Inc. ACTU | NCT03678883 9-ING-41 in Patients With Advanced Cancers | Cancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractory | active not recruiting | 350 |
| 2026-05-31 est. | P2 | Ascentage Pharma Group Inc. AAPG | NCT04496349 A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL | T-Prolymphocytic Leukemia; Non-Hodgkins Lymphoma | recruiting | 78 |
| 2026-05-27 | P1/P2 | Lakefront Biotherapeutics NV LKFT | NCT06561425 A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma; Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell | terminated | 130 |
| 2026-05-23 | P2 | Hutchmed HCM | NCT06601504 Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | completed | 61 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "lymphoma"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.